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Abstract
Background: Bronchoscopic cryobiopsy is a new method of bronchoscopic tissue sampling in interstitial lung
disease. In case of transbronchial biopsies, the resultant tissue samples are of high quality, and the lung
parenchyma seen in the samples is adequate for a histological diagnosis in most cases. Bleeding after
transbronchial biopsy is the most important procedure- associated complication and may be life threatening. This
study addresses the risk of bleeding of transbronchial cryobiopsy.
Methods: In this prospective, randomized, controlled multicentre study 359 patients with interstitial lung disease
requiring diagnostic bronchoscopic tissue sampling were included. Both conventional transbronchial forceps biopsy
and transbronchial cryobiopsy were undertaken in each patient. The sequence of the procedures was randomized.
Bleeding severity was evaluated semi-quantitatively as “no bleeding”, “mild” (suction alone), “moderate” (additional
intervention) or “severe” (prolonged monitoring necessary or fatal outcome), for each intervention.
Results: In 359 patients atotal of 1160 cryobiopsies and 1302 forceps biopsies were performed. Bleeding was
observed after forceps biopsy in 173 patients (48.2%) and after cryobiopsy in 261 patients (72.7%).
Bleeding was significantly greater in the cryobiopsy group (cryobiopsy/forceps biopsy: no bleeding 27.3%/51.8%;
mild 56.5%/44.0%; moderate 15.0%/4.2%; severe 1.2%/0%; p < 0.001). The rate of clinically relevant bleeding
(moderate or severe) was higher after the cryobiopsy procedures compared to the forceps biopsies
(16.2% vs. 4.2%, p < 0.05). No fatal bleeding complications occurred.
Conclusions: Compared to transbronchial forceps biopsy, transbronchial cryobiopsy was associated with an
increased risk of bleeding which is of clinical relevance. Therefore training and additional precautions for bleeding
control should be considered.
Trial registration: The study was registered with clinicaltrials.gov (NCT01894113).
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Background
Diagnosis of interstitial lung diseases remains a chal-
lenge. Although, in some cases, the diagnosis can be
made on the basis of clinical and radiological data alone,
tissue sampling for histological evaluation is needed in a
significant proportion of patients [1–3]. However, distin-
guishing the different types of interstitial lung disease
(ILD) is crucial due to its prognostic impact and inform-
ing different therapeutic interventions. With a diagnostic
yield of 86 to 92% surgical lung biopsy (SLB) exceeds the
sensitivity of conventional transbronchial lung forceps
biopsy (TBFB) and is therefore recommended in the
current guidelines for adequate tissue sampling in pa-
tients with suspected idiopathic interstitial pneumonias
[4–7]. However SLB’s are associated with a significant
mortality rate - 1.7% in elective patients, and up to be-
tween 16% [8] and 21.7% [9] in non-elective patients.
These data highlight the need for less invasive, and safer,
high yield diagnostic sampling methods.
Transbronchial lung cryobiopsy (TBCB) now meets
this need with its larger specimens [10, 11] and reduced
tissue artefacts [10, 12, 13], markedly improving the
diagnostic yield compared to TBFB [10, 14–17]. In
combination with clinical and radiological information,
TBCB provides substantial additional diagnostic infor-
mation and reaches a similar confidence level in idio-
pathic pulmonary fibrosis (IPF) diagnosis to that of SLB
[18]. However it is unclear what the cost of this add-
itional information is in terms of a higher complication
rate. Several, mostly retrospective papers, reported high
pneumothorax rates, severe bleeding complications and
a few cases of fatal exacerbations after transbronchial
cryobiopsies [19, 20]. Whereas the number of exacerba-
tions was low, and pneumothoraces could be managed
relatively easily, bleeding after TBCB remains the main
concern.
To establish comparative safety profiles we performed
a trial to evaluate complication rates of TBCB compared
to TBFB in patients with ILD requiring tissue sampling
for diagnosis.
Methods
This prospective, randomized, multicentre study was
performed in six pulmonary centers in Germany.
Study population
Patients with radiologically proven ILD requiring
histological examination for further evaluation were
chosen for inclusion in this study. All patients were
over 18 years old. Signed informed consent was
mandatory. Exclusion criteria included any possible
bleeding disorders (international normalized ratio (INR) >
1.3, partial thromboplastin time (PTT) above normal
range, thrombocytopenia < 100.000/μl), treatment with
thienopyridines, oxygen saturation below 90% after deliv-
ery of oxygen at a maximum flow rate of 2 l per minute,
pre-existing severe cardiac diseases (e.g. instable angina
pectoris, myocardial infarction, decompensated cardiac
insufficiency) or known echocardiographically measured
pulmonary hypertension with a systolic pulmonary artery
pressure greater than 50mmHg. While treatment with
clopidogrel and other new antiplatelet drugs had to be
stopped periinterventionally, treatment with acetylsalicylic
acid could be continued.
Bronchoscopy
Bronchoscopy was performed with either a flexible or
rigid technique, depending on the operator’s choice. In
case of flexible bronchoscopy placement of an endo-
tracheal tube was recommended in order to provide a
secure airway. When rigid bronchoscopy was under-
taken, tissue biopsy was carried out by using the flexible
bronchoscope inserted through the rigid tube. General
anaesthesia for rigid bronchoscopy, deep sedation and
local anaesthesia for intubation with a flexible tube and
patients’ monitoring, including continuous oxygen
saturation, ECG monitoring and repeated non-invasive
blood pressure monitoring, were performed according to
the local standard of each centre.
Tissue sampling
In every patient both conventional transbronchial forceps
and cryobiopsy techniques were performed. The sequence
of the biopsy techniques was randomized. Fluoroscopy
guidance was recommended for both techniques. For
cryobiopsy a distance of 1 cm from the visceral pleura was
recommended. TBCB was performed using cryoprobes of
1.9 or 2.4 mm diameter (Erbe Elektromedizin GmbH,
Tübingen, Germany) and a freezing time of 3 to 7 s
depending on the freezing power and diameter of the
cryoprobe. TBFB biopsy was performed using forceps of a
diameter between 1.8mm and 2.6mm.
Data acquisition
Demographic data were documented. Bleeding was
predefined as described below.
Evaluation of bleeding
The different biopsy techniques TBCB and TBFB were
evaluated for occurrence of bleeding. As several biopsies
were taken using each technique, the most severe
bleeding from each technique was documented. Bleeding
severity was determined on a four-point scale: none;
mild bleeding: (self-limiting bleeding, manageable with
suction alone and without the need for any specific
intervention); moderate bleeding: (use of any additional
intervention such as instillation of ice-cold saline or
vasoconstrictive drugs, or transient balloon tamponade
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in order to prevent bleeding in the central airways); se-
vere bleeding: additional prolonged monitoring or inten-
sive care therapy after the procedure was necessary or if
the bleeding was fatal. Prophylactic balloon placement
was not performed.
Evaluation of pneumothorax
Occurrence of pneumothorax was evaluated by conven-
tional chest X-ray between one and two hours following
the bronchoscopy.
Randomization
The sequence of biopsy techniques (TBFB or TBCB)
was randomized using consecutive numbered envelopes
for randomization at each study site. The Institute of
Epidemiology and Medical Biometry, Ulm University,
Ulm, Germany, provided randomization envelopes and
reviewed adherence to randomization at the end of the
study.
Statistics
The incidence and severity of bleeding, being the
primary aim of this study, was given by relative and
absolute frequencies and were compared using the
McNemar-Bowkertest for categorical and Wilcoxon
signed rank test for continuous outcomes. Carry over
effect was ruled out beforehand. Fisher’s exact test was
used for comparisons in contingency tables for
independent (sub)groups. A p-level < 0.05 was regarded
as significant. Statistical analysis was done by JMP 13.1
and supported by the Institute of Epidemiology and
Medical Biometry, Ulm University, Germany.
The study design and protocol was approved by the
Ethics Committees of Tuebingen (Reference number
035/2011MPG23) and confirmed by each individual site
ethics committee.
Results
In this multicentre study a total number of 381 patients
were included in 6 German pulmonary centres. 11
randomized patients had to be excluded due to an
incomplete diagnostic procedure with none, or only one,
biopsy technique (Fig. 1). In 6 patients the second biopsy
technique was not performed because of moderate
bleeding after the first technique (in 5 patients after
TBCB, in one case after TBFB). In one case a pneumo-
thorax after TBCB occurred, thus TBFB was not
performed. In the remaining 370 patients bleeding
quantification was missing in 8 patients in the forceps
biopsy group and in 3 patients in the cryobiopsy group,
resulting in a final study population of 359 patients.
Patient characteristics
Patient characteristics are summarized in Table 1.
Bronchoscopic intervention
Specification of the bronchoscopic intervention, number
of biopsies which each technique, sedation, intubation
TBLB – transbronchial lung biopsy; TBCB – transbronchial lung cryobiopsy; TBFB – transbronchial lung 
forceps biopsy
381 Patients were included in the 
study
11 Patients were excluded due to incomplete diagnostic 
procedure
1 - No TBLB due to presence of endobronchial lesion
3 - TBLB was not possible for any reason
7 - Only one TBLB technique was performed
- 6 cases only TBCB
- 1 cases only TBFB
11 Patients were excluded due to incomplete evaluation of 
bleeding 
8 - No evaluation after TBFB
3 - No evaluation after TBCB
359 Patients were included in the 
final analysis
Fig. 1 Study population. TBLB – transbronchial lung biopsy; TBCB – transbronchial lung cryobiopsy; TBFB – transbronchial lung forceps biopsy
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technique and size of biopsy probes are summarized in
Table 2. Localization for biopsy site, and the size of the
biopsy tool was left to individual choice. TBCB was per-
formed in just one lobe in 205 patients, and from 2 dif-
ferent lobes in 151 patients, with a total of 1160
cryobiopsies being taken. Forceps biopsy was performed
in one lobe in 166 patients and multiple lobes in 189 pa-
tients. Forceps biopsies were performed in multiple lobes
in significantly more patients (p = 0.004), with a total of
1302 biopsies. Forceps biopsies were taken in the upper
lobe in 39.6% and in the lower lobe in 60.4% of patients,
whereas cryobiopsies were taken in the upper lobe in
36.0% and in the lower lobe in 64.0% of patients. There
were significantly more biopsies performed in the right
lung compared to the left lung (cryobiopsy: 812 (70.0%),
forceps biopsy: 900 (69.1%)) (Table 2).
Incidence and severity of biopsy related bleeding
The severity of biopsy related bleeding comparing the
two different biopsy techniques is summarized in Table 3
and Fig. 2. Bleeding severity was significantly higher after
TBCB compared to TBFB. Using the categorization of
bleeding described above, we observed none, mild, mod-
erate and severe bleeding in 98 (27.3%), 203 (56.5%), 54
(15.0%) and 3 (1.1%) patients after TBCB compared to
186 (51.8%), 158 (44.0%), 15 (4.2%) and 0 (0%) cases
after TBFB (p < 0,001). Bleeding occurred more often
in the TBCB group (bleeding in 261 cases (72.7%),
none in 98 cases (27.3%)) compared to the TBFB
group (bleeding in 173 cases (48.2%), none in 186
cases (51.3%)) (p < 0.001).
Bleeding severity was categorized as bleeding of low
clinical relevance (none or mild) and high clinical rele-
vance (moderate or severe). We observed a significantly
higher incidence of bleeding of high clinical relevance
(moderate or severe) in the TBCB group (58 patients
(16.2%)) compared to the TBFB biopsy group (15 pa-
tients (4.2%) (p < 0,001)). There were no cases of severe
bleeding after TBFB, but 4 cases after TBCB. They had a
normal coagulation status, one patient was on aspirin. In
those 4 patients endobronchial vasoconstrictive drugs
were instilled, and in two cases a local bronchial block-
age with a Fogarty balloon was also applied. In all cases
bleeding could be controlled during the bronchoscopy.
One of those patients, who had already suffered from an
exacerbation of his fibrosing interstitial lung disease
prior to the bronchoscopy, died within 30 days after
bronchoscopy. After the bronchoscopy and biopsy with
both techniques, oro-tracheal intubation and transient
mechanical ventilation was needed because he had
respiratory failure. One day after the procedure he could
be extubated. However one day after extubation he
developed acute cardiac insufficiency with consecutive
respiratory failure, which could not be stabilized, and the
patient died 6 days after the procedure.
The bleeding severity wasn’t influenced by the biopsy
sequence for either technique.
Incidence/severity of bleeding regarding patient
characteristics and bronchoscopic intervention
In the TBCB group we found significant more bleeding
of high clinical relevance (moderate/severe) in those
age > = 65 years compared to those < 65 years (Table 4).
In the TBCB group we observed significantly more
highly clinically relevant bleeding in patients with a
height < = 170 cm. Furthermore females showed a sig-
nificant higher clinically relevant bleeding rate than men
when the biopsies were taken with the cryoprobe. Simi-
larly in the TBFB we observed significantly more highly
clinically relevant bleeding in patients <= 170 cm than
those > 170 cm. However there was no relationship com-
paring bleeding with sex and age. Comparison of bleed-
ing severity independent of the applied biopsy technique
(TBCB and TBFB) showed significant more bleeding in
older patients (> = 65 yrs), females, and patients with a
body height < =170 cm.
Table 1 Characteristics of the Patients*
Variable N = 359 (100%)
Age – yrs 62.8 (±14.0)
Sex – no. (%)
Female 153 (42.6)
Male 198 (55.2)
Weight – kg 78.0 (±15.7)
Body height – cm 169.3 (±10.0)
Smoking status – no. (%)
Non-smoker 132 (36.8)
Ex-smoker 138 (38.4)
Current Smoker 62 (17.3)
Smoking index – pack years
Ex-smoker 24.9 (±18.8)
Current smoker 32.1 (±20.9)
Coagulation profile
Prothrombin time (INR) 1.02 (±0.12)
Partial thromboplastin time (PTT) – sec 28.8 (±5.8)
Thrombocytes – × 1000/μl 271 (±161)
Aspirin – no. (%)
Yes 51 (14.2)
No 303 (84.6)
*Plus-minus values are means ± Standard deviation (SD). Patient characteristics
were unknown for age in 10 patients (2.8%), for sex in 8 patients (2.2%),
weight and height in 17 patients (4.7%), smoking status in 27 patients (7.5%),
prothrombin time (INR) in 8 patients (2.2%), partial thromboplastin time (PTT)
in 27 patients (7.5%), thrombocyte count in 15 patients (4.2%) and for aspirin
intake in 5 patients (1.4%)
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There were no significant differences in bleeding of
either low or high clinical relevance in relation to coagu-
lation profile (INR, PTT or thrombocyte count) between
TBCB and TBFB. Treatment with low dose aspirin
showed a trend (p = 0.067) to more highly clinically
relevant bleeding in the TBCB group, whereas no
difference could be observed in the TBFB group.
Analyses of biopsy-related bleeding in relation to
different bronchoscopic intervention parameters (biopsy
localization and probe size) are shown in Table 5. Use of
small probes compared to large probes showed signifi-
cantly less clinically relevant bleeding in the cryobiopsy
group (p = 0.006) whereas in the forceps biopsy group a
trend to less bleeding with small probes could be
observed (p = 0.12). Comparison of the small cryobiopsy
probe with the large forceps biopsy probe showed
significantly more clinically relevant bleeding with the
cryobiopsy (p < 0.001).
In case of bleeding of moderate to severe categories, a
combination of one or more of the following bleeding
control interventions was performed: instillation of
drugs (cold saline in 49 cases, Xylometazolin in 62 cases,
adrenalin in 11 cases, tranexamic acid in 1 cases),
balloon tamponade in 13 cases, temporary tamponade a
gauze compress in 3 cases and wedging with the
bronchoscope followed by intubation and controlled
ventilation in one case.
Table 2 Bronchoscopic intervention*
Variable N = 359 (100%)
Number of biopsies
Cryobiopsy
Total number of cryobiopsies 1160
Cryobiopsies per patient 3,2 ± 1,2
Forceps biopsy
Total number of forceps biopsies 1302
Forceps biopsies per patient 3,6 ± 1,2
Sedation – no. (%)
General anaesthesia 169 (47.1)
Deep sedation 185 (51.5)
Deep sedation
Midazolam
Number of patients 115
Dose – mg 3.57 (±1.66)
Propofol
Number of patients 168
Dose – mg 315.2 (±166.9)
Intubation technique – no. (%)
Rigid bronchoscope 169 (47.6)
Endotracheal tube intubation 182 (51.3)
No intubation 4 (1.1)
Probe size
Cryobiopsy – no. (%)
Small
1.9 mm 212 (59.1)
Large
2.4 mm 145 (40.4)
Forceps – no. (%)
Small
total 169 (47.1)
1.8 mm 145 (40.4)
2.0 mm 24 (6.7)
Large
total 186 (51.8)
2.2 mm 161 (44.8)
2.6 mm 25 (7.0)
Biopsy technique
TBCB TBFB
Localization of biopsy - no. (%)
Biopsy in different lobes 151 (42.1) 189 (52.6)
Biopsy in just one lobe 205 (57.1) 166 (46.2)
Right upper lobe and middle lobe 284 (24.5) 357 (27.4)
Table 2 Bronchoscopic intervention* (Continued)
Variable N = 359 (100%)
Left upper lobe 134 (11.6) 159 (12.2)
Right lower lobe 528 (45.5) 543 (41.7)
Left lower lobe 214 (18.4) 243 (18.7)
*Plus-minus values are means ± Standard deviation (SD). Data were unknown
as follows: for sedation in 5 patients (1.4%), midazolam application in 15
patients (4.2%), propofol application in 30 patients (8.4%), intubation
technique in 4 patients (1.1%), probe size of cryobiopsy in 1 patient (0.3%),
and probe size of forceps in 4 patients (1.1%) and localization of cryobiopsy/
forceps biopsy in 4/ 4 patients (1.1/ 1.1%). TBCB – transbronchial lung
cryobiopsy; TBFB – transbronchial lung forceps biopsy
Table 3 Severity of biopsy- related bleeding*
TBCB N = 359 (100%)
Bleeding– no. (%) None
98 (27.3)
Mild
203 (56.5)
Moderate
54 (15.0)
Severe
4 (1.1)
TBFB N = 359 (100%)
None 186 (51.8) 82 (22.8) 88 (24.5) 14 (3.9) 2 (0.6)
Mild 158 (44.0) 14 (3.9) 111 (30.9) 31 (8.6) 2 (0.6)
Moderate 15 (4.2) 2 (0.6) 4 (1.1) 9 (2.5) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severity of biopsy-related bleeding, comparing both techniques (TBCB –
transbronchial lung cryobiopsy; TBFB – transbronchial lung forceps biopsy) for
each patient. Severity of bleeding was categorized as no, mild, moderate and
severe bleeding as defined above. Difference in bleeding incidence was significant
different over all categories (*p< 0.001, calculated by the Bowker’s test)
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Table 4 Incidence and severity of bleeding related to patient characteristics*
Technique
Cryobiopsy (N = 359) Forceps biopsy (N = 359)
Bleeding severity None/Mild Moderate/Severe p-value None/Mild Moderate/Severe p-value
Clinical relevance Low High Low High
all – no (%) 301 (83.8) 58 (16.2) – 344 (95.8) 15 (4.2) –
n
Age 349
< 65 yr 160 143 17 0.018 155 5 0.59
> = 65 yr 189 151 38 180 9
Sex 351
Female 153 121 32 0.026 145 8 0.41
Male 198 175 23 192 6
Body height 342
= < 170 cm 186 146 40 0.002 175 11 0.043
> 170 cm 156 142 14 154 2
Smoking 332
Non-smoker 132 109 23 0.52 124 8 0.27
Ex-smoker 138 118 20 135 3
Current smoker 62 55 7 59 3
Aspirin 354
Yes 51 38 13 0.067 49 2 1.0
No 303 258 45 290 13
*Clinical relevance of bleeding is categorized as “low” (none, and mild bleeding) and “high” (moderate and severe bleeding) for both biopsy techniques. Absolute
number (n) of evaluable patients are listed in the second column. Data were missing for age in 10 patients (2.8%), sex in 8 patients (2.2%), body height in 17
patients (4.7%), smoking status in 27 patients (7.5%), and for aspirin use in 5 patients (1.4%). P-values were calculated by 2 tail Fisher’s exact test for independent
samples focusing on each technique separately
Fig. 2 Severity of biopsy-related bleeding, comparing both techniques.
(TBCB – transbronchial lung cryobiopsy; TBFB – transbronchial lung forceps biopsy)
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Correlation between relevance of bleeding and patient’s
height
Since both the size of cryoprobes and the patient’s’
height were associated with bleeding severity, we ana-
lysed relevance of bleeding (as calculated by the ratio of
relevant bleeding to non-relevant bleeding) in relation to
both factors. The increase of clinically relevant bleeding
with the large cryoprobe in comparison to the small
cryoprobe was higher in patients <= 170 cm (45.3 vs
17.2%, 2.63fold) compared to patients > 170 cm (12.3
vs 8.3%, 1.47fold) (Table 6). Whereas the proportion of
relevant bleeding was significantly higher with the large
cryoprobes in patients = < 170 cm (p < 0.05), this was not
the case for patients > 170 cm.
Incidence of periinterventional pneumothorax
27 patients (7.5%) developed a pneumothorax after
TBCB and TBFB. There was no significant difference in
the rate of pneumothoraces between patients having
TBCB with the small or the large cryoprobes.
Discussion
Bleeding is the main peri-procedural complication of
interventional bronchoscopic techniques and is also the
main complication of TBCB. This may be a life-
threatening situation and is therefore of high clinical
relevance. The severity of bleeding is very difficult to
quantify as it is influenced by two factors which are
difficult to measure. The first factor is the bleeding
quantity - the absolute amount of endobronchial blood.
The second, probably more important factor, is the
bleeding intensity – the blood flow per unit time. The
volumes in each case may also be influenced by
additional fluids inserted via the bronchoscope, and the
variable retrieval rate of any intra-bronchial fluid. There-
fore current rating classifications of bleeding severity are
based on subjective assessments. Studies evaluating
TBCB have reported a wide range of bleeding complica-
tions, which illustrates the lack of a valid scale [19].
In order to overcome this limitation we have com-
bined three approaches to quantify bleeding.
Firstly we have used the clinical and therapeutic
consequences of endobronchial bleeding as criteria to
scale bleeding severity semi-quantitatively with “bleeding
was controlled by suction alone” as “mild” bleeding or
“the patient had to have prolonged monitoring or
intensive care therapy due to the bleeding” as “severe”
bleeding. This method based on clinical consequences
exactly mirrors the clinical relevance.
Table 6 Influence of the size of the cryoprobe and patient’s
height on clinical relevance of bleeding
Relevant bleeding/Non- rel. Bleeding (%) Patient‘s height
= < 170 cm > 170 cm
Size of cryo probe Small (1.9 mm) 17.2 8.3
Large (2.4 mm) 45.3 12.3
Table 5 Incidence and severity of bleeding regarding bronchoscopic intervention
Technique
Cryobiopsy (N = 359) Forceps biopsy (N = 359)
Bleeding severity None/Mild Moderate/Severe None/Mild Moderate/Severe p- value
Clinical relevance Low High Low High
Intervention – no (%) 301 (83.8) 58 (16.2) 344 (95.8) 15 (4.2) TBCB vs TBFB < 0.001
Probe size
Cryobiopsy 357
Small: 1.9 mm 211 187 25 SC vs. LC: p = 0.006
SC vs. LF: p < 0.001Large: 2.4 mm 146 112 33
Forceps 355
Small: 1.8–2.0 mm 169 165 4 SF vs. LF: p = 0.12
Large: 2.2–2.6 mm 186 175 11
Localization of biopsy
Upper lobe 48 13 p = 1.0
Lower lobe 112 32
Upper lobe 49 4 p = 0.27
Lower lobe 109 4
*Clinical relevance of bleeding is categorized as “low” (None, and mild bleeding) and “high” (moderate and severe bleeding) for both biopsy techniques. Absolute
number of evaluable patients is listed in the second column. P-values were calculated by 2 tail Fisher’s exact test for independent samples, comparing small
cryobiopsy (SC) and large cryobiopsy (LC), small forceps biopsy (SF) and large forceps biopsy (LF) as well as small cryobiopsy (SC) and large forceps biopsy (LF)
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Secondly we compared bleeding caused by TBCB as a
“new” technique with a well-known and established
technique. We chose the TBFB as the comparator to
TBCB. This strategy offers two advantages: firstly, the
severity of bleeding after TBFB is well known among
bronchoscopists, and therefore bleeding after TBCB can
be assessed in relation to TBFB much more easily and
precisely. The second advantage is that the use of a
comparator minimizes individual subjective variance in
the rating of the two techniques, although the use of any
scale based on clinical and bronchoscopic consequences
remains subjective and thus variable between individuals.
However, since each bronchoscopist applies their own
subjective rating scale on both biopsy techniques, com-
parison is valid.
Thirdly, we compared bleeding severity of both biopsy
techniques in the same patient in a randomized se-
quence in order to minimize the influence of individual
patient characteristics such as the underlying lung dis-
ease, coagulation status or pre-procedure haemodynamic
status.
This prospective randomized multicentre trial has re-
vealed that TBCB caused a higher incidence and signifi-
cantly more clinically relevant endobronchial bleeding
compared to TBFB. In each participating centre a trend
towards more bleeding in the cryobiopsy group could be
observed. Any bias within a single centre is reduced by
the multi-centre design of the study. In the cryobiopsy
group 84% of the patients showed no bleeding at all, or
only a mild bleeding controllable by suction alone,
compared to 96% in the forceps group. Thus in 16% of
the patients after TBCB additional procedures had to be
performed in order to control bleeding, confirming
greater clinically relevant bleeding after TBCB than
TBFB. It has to be emphasized that a prophylactic bal-
loon placement for protection of the central airways, as
described in other studies [21], was not been performed
in this study. Therefore the judgement on bleeding
severity in the cryobiopsy group wasn’t compromised by
the tamponade, and therefore true comparison of
bleeding between the two groups has been possible.
There was a great diversity of methods used to
control bleeding in this study. This variety in
technique for bleeding control indicates that there is
currently no consensus as to the best method for
bleeding control, and this area requires further study.
Comparing the principal methods, endobronchial in-
stallation of drugs and endobronchial tamponade, it is
clear that only tamponade results in the immediate
protection of the non-biopsied lung areas.
The number of biopsies taken could have influenced
the results; the more biopsies, the higher the probability
of more severe bleeding. The median number of biopsies
performed was higher for TBFB (3.6 biopsies per
patient) compared to TBCB (3.2 biopsies per patient).
Therefore, the observed difference in bleeding severity
cannot be explained by the difference in the number of
biopsies of the two different techniques. The sequence
of the biopsy techniques did not influence bleeding.
The bleeding severity could also have been influenced
by the site of each biopsy. Although fluoroscopy was
used to determine comparable biopsy areas, equality of
the distance to the pleura cannot be guaranteed by
either fluoroscopy or by withdrawal distance from the
position where the probe cannot be passed further.
Bleeding may have also been influenced by any imbal-
ance in the number of biopsies from different lobes of
the lung. We observed a tendency towards a higher
proportion of TBFB (40%) in the upper lobe compared
to TBCB (36%, p = 0.066), which may have influenced
our results. To exclude this potential bias we compared
bleeding severity in those patients in whom a certain
technique was performed only in one lobe, but not in
different lobes. We couldn’t observe any difference in
bleeding severity between the lower lobe and the upper
lobe for each technique. Therefore it is unlikely, that the
tendency towards an imbalance in the distribution of
biopsies between upper and lower lobe has influenced
our results. In a similar manner, the difference in the
higher proportion of patients in the forceps group, who
were biopsied in both lobes, does not appear to have
affected the bleeding rate either.
Interestingly, body height correlated with a higher
bleeding risk: the shorter the patient the higher the
bleeding risk. In addition in the cryobiopsy group
female patients showed a significantly higher bleeding
risk than male patients. These differences are difficult
to explain as multiple factors may have influenced
these results. However, one explanation has to be
considered, namely that body height is correlated with
the size of the lungs. Therefore the relative size of
the biopsy tool in relation to the size of the bronchi
is increased in smaller patients. As a result, position-
ing of the cryoprobe in the small bronchioli of the
lung periphery, where the blood vessels are smaller,
may be more difficult to achieve in smaller patients.
Furthermore in relation to the pulmonary structures
the resultant biopsy samples are bigger. Both factors
may increase the risk of damaging larger vessels, and
therefore increase the risk of bleeding. This hypoth-
esis is supported by the fact that the relative increase
of bleeding-risk with a large cryoprobe compared to a
small cryoprobe is higher in shorter patients com-
pared to taller patients (large cryoprobe: 2.63 fold
increase; small cryoprobe 1.47 fold increase).
However, one limitation of the subgroup analyses is
that we assumed a relation between body height and
lung volume, which is quite reasonable, but this was
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not measured in the study setting and therefore
confirmatory data is not available. Gender and age
also influence the lung size with female and older pa-
tients having smaller lungs. As female patients and
older patients showed a higher bleeding risk in the
cryobiopsy group this correlation supports the causal
relationship between lung size and bleeding risk.
As treatment with aspirin has not been shown to be
associated definitively with an increased risk of bleeding,
patients on aspirin were included in the present trial
[22]. Our present data confirm these previous results,
with a bleeding risk after forceps biopsy which was not
different with or without aspirin treatment. However the
low incidence of clinically relevant bleeding limits the
validity of such statistical testing.
In contrast to forceps biopsy, in the cryobiopsy group
there was a tendency to more severe bleeding in patients
treated with aspirin. In combination with the higher
absolute number of moderate and severe bleeding, this
may be clinically relevant.
Another complication of TBCB is the rate of
pneumothoraces. Although it is impossible to assign
any pneumothorax to either forceps or cryobiopsies
in this study setting, the overall rate of 7.5% was
relatively low in comparison to other studies [19]. It
has to be emphasized that the number of cryobiopsies
per patient was comparable to the other studies.
Therefore the lower amount of pneumothoraces
compared to previous cryobiopsy studies cannot be
explained by a lower number of cryobiopsies. It is
possible that the low number of pneumothoraces in
our study may be due to operator’s experience, since
most published studies relate to an earlier period
following development of the technique.
We observed one fatal outcome in a patient with acute
exacerbation prior to the intervention; this underlines
the importance for strict selection of stable patients for
transbronchial biopsy.
In summary, this prospective, randomized, multicen-
tre and so far the largest study on TBCB, reveals that
bleeding is a clinically relevant risk factor in TBCB
which is greater than for TBFB. Based on this obser-
vation, with a frequency of 16% for clinically relevant
bleeding after TBCB, it can be concluded that any
procedure using TBCB should ensure protection of
the airways, either by using rigid bronchoscopy or the
placement of an endotracheal tube. Also precautions
for bleeding control, such as prophylactic balloon
placement, are recommended. Methods to increase
the safety of TBCB increase its risk/benefit ratio and
therefore justify the use of TBCB to obtain the
superior histological and clinically relevant material. It
is necessary to place the risk of TBCB in the context
with the risk of a more invasive surgical biopsy when
making decisions as to the most relevant biopsy pro-
cedure used to obtain diagnostic histological material
in each individual patient. This study has not directly
compared the two methods of TBCB vs surgical
biopsy, and such comparisons are difficult with the
large numbers of possible variables including patient
selection. However, our study has clearly shown that
TBCB can be carried out without significant compli-
cation in the majority of patients.
Conclusion
Our study shows that transbronchial cryobiopsy was
associated with an increased risk of bleeding
compared to transbronchial forceps biopsy. This side
effect is clinically relevant. Therefore training and
additional precautions for bleeding control should be
considered.
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